Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls. Further analyses identified a discrete subset of the treatment group that demonstrated especially robust responses ("responders"), suggesting that these patients could be identified prior to treatment.
Fuente : http://www.eurekalert.org/pub_releases/2013-08/itn...
Fuente : http://www.eurekalert.org/pub_releases/2013-08/itn...